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Background: This randomized controlled study evaluated the efficacy of intravenous patient-controlled analgesia 
(IV-PCA) with fentanyl and ketorolac for neurosurgical patients, and compared the effectiveness of IV-PCA with 
intermittent analgesics injection.
Methods: The patients undergoing craniotomy were randomly assigned to two groups. Patients of group P (n = 53) 
received fentanyl (0.2 μg/kg/hr) and ketorolac (0.3 mg/kg/hr) via IV-PCA, and those of group N (n = 53) received 
intermittent fentanyl or ketorolac injection as needed. Pain was evaluated using a 0-10 visual analogue scale (VAS) 
at postoperative 1, 4, and 24 hr. The amount of infused analgesic drugs, Glasgow Coma Scale (GCS) score, systolic 
arterial pressure, heart rate, respiratory rate, and the incidence of nausea and miosis were measured at the same time 
points.
Results: Although VAS of pain (VASp) was comparable at postoperative 1 hr (P = 0.168) between the two groups, the 
group P had significantly lower VASp at postoperative 4 hr (P = 0.007) and 24 hr (P = 0.017). In group P, less analgesic 
drugs were administered at postoperative 1 hr, and more analgesic drugs were administered at postoperative 24 hr. 
There were no differences between two groups with respect to nausea, GCS, systolic arterial pressure, and heart rate. 
IV-PCA did not further incur respiratory depression or miosis.
Conclusions: IV-PCA with fentanyl and ketorolac after craniotomy is more effective analgesic technique, without 
adverse events, than the intermittent administration of analgesics. (Korean J Anesthesiol 2011; 60: 30-35)
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Introduction
    It was generally thought that patients undergoing craniotomy 
experience minimal pain during the postoperative period. 
However, the recent reports have indicated that post-craniotomy 
pain is a real headache and more severe than anticipated [1]. It 
was sometimes managed insufficiently and treated with only 
on-demand analgesic medication. Intramuscular codeine 
phosphate was reported to be the first-line drug for relieving 
post-craniotomy pain in the majority of the neurosurgical 
centers of the UK in 2005 [2]. 
    Insufficient pain control after craniotomy can increase the 
intracranial pressure in patients with compromised cerebral 
autoregulation, and arterial or intracranial hypertension can 
lead to intracranial hemorrhage. Moreover, most neurosurgeons 
want to ascertain the neurological results as early as possible, so 
cautious postoperative pain management is required so as not 
to disturb the neurological assessment after craniotomy.
    The superiority of potent opioids such as morphine, codeine 
and oxycodone rather than weak analgesics has been proved in 
neurosurgical patients [3-6], and scalp nerve block has also been 
tried [7] for achieving better pain relief in craniotomy patients. 
Intravenous patient-controlled analgesia (IV-PCA) using both 
opioids and NSAIDs is a common method for the treatment of 
acute postoperative pain after general surgery [8-12] because it 
is possible to maximize the analgesic effect through the different 
mechanisms of the drugs while at the same time not increasing 
the side effects. Although some neuroanesthesiologists 
have pointed out that the postcraniotomy patients are too 
uncooperative to benefit from PCA [13], early recovery has been 
a current trend after intracranial procedures, so we think that 
IV-PCA can be used by these patients. 
    We evaluated the efficacy and safety of IV-PCA composed 
of fentanyl and ketorolac in postcraniotomy patients by 
conducting this randomized controlled study. 
Materials and Methods
    After getting approval from the Institutional Review Board, 
informed written consent was obtained from all the patients 
scheduled for elective intracranial surgery. This randomized 
controlled trial was conducted on patients with a physical status 
of I or II according to the American Society of Anesthesiologist 
classification. The eligible criteria were preoperative Glasgow 
Coma Scale (GCS) score of 15 and female or male adults 
aged 20-70. The preoperative exclusion criteria were as 
follows: morbid obesity, prolonged postoperative ventilatory 
care, difficulty in using IV-PCA, and chronic medication 
with analgesics and other drugs that could influence 
the postoperative pain (steroid, antiepileptic drugs and 
gabapentin).
    Patients were randomly assigned to two groups using the 
sealed envelope method; the IV-PCA group (group P) or the 
intermittent analgesic drugs injection group (group N). We 
explained the 0-10 visual analogue scale (VAS) ruler assessing 
the postoperative pain to all the patients, and gave detailed 
instruction for the IV-PCA to the patients of group P. The IV-
PCA (AutoMed
Ⓡ 3200, ACE Medical Corp., Ltd, Seoul, Korea) 
of group P was composed of fentanyl and ketorolac. Fentanyl 
20 μg/kg and ketorolac 3 mg/kg (rounded off to the nearest 
multiple of 50 μg and 10 mg, respectively) were made up to 100 
ml in normal saline and the infusion rate, bolus dose, and lock 
time interval were set at 1 ml/hr, 1 ml, and 15 min, respectively 
[14].
    Standard monitoring (ECG, non-invasive arterial pressure, 
and pulse oximetry) was established in the operating room. 
Anesthesia was induced and maintained using propofol and 
remifentanil by target controlled infusions (TCI) using an 
Orchestra
Ⓡ infusion pump system (Fresenius vial, Brezins, 
France). After loss of consciousness, neuromuscular block was 
achieved with rocuronium 0.6 mg/kg, followed by tracheal 
intubation. Patients were ventilated with 50% oxygen in air with 
maintaining the end-tidal CO2 level between 30-35 mmHg. 
Both invasive arterial pressure and central venous pressure 
were monitored in each patient as routine practice. Propofol 
and remifentanil were discontinued after skin closure and IV-
PCA was started for the patients of group P. After the operation, 
patients were transferred to the intensive care unit (ICU) and 
extubation was performed after recovery from the anesthesia.
    During the postoperative period, the patients of group P 
used the IV-PCA according to the prior instruction. In group N, 
when patients complained of pain, VAS score of pain (VASp) 
was checked and if necessary, a rescue analgesic drug such as 
ketorolac or fentanyl was administered. If VASp was 7 or more, 
then 1 μg/kg of fentanyl was administered, and if VASp was 
4-6, 0.5 μg/kg of fentanyl was used. When VASp was 2 or 3, 
30 mg of ketorolac was injected, and no additional analgesics 
were administered for VASp of 0 or 1. This was determined with 
considering the basal and bolus doses of IV-PCA in group P 
based on the VASp of 1-3 = mild pain, 4-6 = moderate pain, 
and 7-10 = severe pain [15].
    VASp and the cumulative amount of infused analgesic drugs 
were assessed at postoperative 1, 4, and 24 hr, and the GCS 
score, pupil size and hemodynamic variables (systolic arterial 
pressure, heart rate, and respiratory rate) were evaluated at 
the same time points. In addition, the incidence of nausea was 
evaluated in both groups. 
    Data were expressed as mean ± SD. The patients’ characte-
ristics were analyzed using Student’s t-test. VASp, the amount 
of infused analgesic drugs, GCS scores, and hemodynamic 32 www.ekja.org
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variables were analyzed by repeated measures ANOVA, and 
when there was a significant difference between the two groups, 
Mann-Whitney U-test was performed at individual time points. 
The incidences of nausea and pupillary miosis, which is a 
constricted pupil less than or equal to 2 mm under ambient 
light, were compared with the chi-square test. In a preliminary 
study, we estimated that 53 patients were required in each 
group to show a difference of 11 (20) in VASp to give a statistical 
power of 80% and a type I error of 5%. Statistical analyses were 
performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, 
USA). P values of <0.05 were considered statistically significant. 
Results
    One hundred twelve patients consented to participate in this 
study. Five patients were excluded during the postoperative 
period because ventilatory support care under sedation 
was intentionally applied for a while, and two patients were 
withdrawn from group P because vomiting required that the 
IV-PCA be stopped. None of the patients had postoperative 
hemorrhage that required surgical removal. Patients’ 
characteristics and surgical data (site of operation and duration 
of anesthesia and operation) are shown in Table 1. 
    Although VASp was comparable between the two groups at 
postoperative 1 hr (P = 0.168), group P had significantly lower 
VASp at postoperative 4 hr (P = 0.007) and 24 hr (P = 0.017) 
(Table 2). In group N, fentanyl (whatever the dose and number 
of injection are) was administered to 46 patients (86.8%) and 
ketorolac was given to 7 patients (13.2%) at postoperative 1 hr. 
Until postoperative 4 hr, fentanyl and ketorolac were injected 
to 34 patients (64.1%) and 14 patients (26.4%), respectively. 
When evaluating at postoperative 24 hr, fentanyl and ketorolac 
were administered to 16 patients (30.2%) and 26 patients 
(49.1%), respectively. Only one patient received no analgesics 
throughout the postoperative 24 hr. The cumulative doses per 
body weight of fentanyl and ketorolac are presented on Table 
2. Patients of group P received significantly less fentanyl and 
ketorolac than group N at postoperative 1 hr (P = 0.001 for 
fentanyl and P < 0.001 for ketorolac), however, the total dose of 
fentanyl and ketorolac of group P was much more than that of 
group N at postoperative 24 hr (P < 0.001 for fentanyl and P = 
0.002 for ketorolac). There was no difference between the two 
groups for the cumulative dose of each drug at postoperative 4 
hr (P = 0.059 for fentanyl and P = 0.085 for ketorolac).
    GCS score was over 13 and it showed no significant differences 
between both groups (Table 3). Hemodynamic variables also 
had no significant differences (Table 3), and pupillary miosis 
Table 1. Patients’ Characteristics and Type of Operation
Group P 
(n = 53)
Group N  
(n = 53)
Age (yr)
Height (cm)
Weight (kg)
Gender (M/F)
Supratentorial/Infratentorial
Operation time (hr)
Anesthesia time (hr)
49.9 ± 15.9
169.7 ± 8.6
62.6 ± 10.1
22/31
42/11
6.7 ± 1.2
7.3 ± 0.9
44.0 ± 13.8
171.4 ± 42.1
65.2 ± 10.2
25/28
37/16
7.0 ± 1.4
7.9 ± 1.1
Values are expressed as mean ± SD or number of patients (n). Group 
P: postoperative use of intravenous PCA for pain control. Group 
N: intermittent analgesic drug administration for postoperative 
pain control. There were no significant differences between the two 
groups. 
Table 2. Postoperative Visual Analogue Scale of Pain and Cumulative 
Amount of Fentanyl and Ketorolac in Two Groups
Group P 
(n = 53)
Group N 
(n = 53)
P value 
VASp-1
VASp-4
VASp-24
Fentanyl-1 
Fentanyl-4 
Fentanyl-24 
Ketorolac-1 
Ketorolac-4 
Ketorolac-24 
4.2 ± 2.5 
 3.3 ± 2.1
 2.3 ± 1.6
0.27 ± 0.05
1.35 ± 0.24
7.42 ± 0.77
0.04 ± 0.01
0.20 ± 0.04
1.10 ± 0.11
5.1 ± 2.2
4.8 ± 2.6
3.4 ± 2.3
0.59 ± 0.44
1.38 ± 0.86
1.75 ± 0.99
0.14 ± 0.23
0.39 ± 0.40
0.87 ± 0.55
0.168
  0.007*
  0.017*
  0.001*
0.590
<0.001*
<0.001*
0.085
  0.002*
Values are expressed as mean ± SD. Group P: postoperative use 
of IV-PCA for pain control. Group N: intermittent analgesic drug 
administration for postoperative pain control. VASp: visual analogue 
scale of the pain. Fentanyl (μg/kg): cumulative dose of fentanyl. 
Ketorolac (mg/kg): cumulative dose of ketorolac. 1, 4 and 24: at 
postoperative 1, 4 and 24 h respectively. *Values are significantly 
different between the two groups.
Table 3. Glasgow Coma Scale and Arterial Systolic Pressure, Heart 
Rate and Respiratory Rate of the Two Groups
Group P (n = 53) Group N (n = 53)
GCS-1
GCS-4
GCS-24
SBP-1 
SBP-4 
SBP-24 
HR-1 
HR-4 
HR-24 
RR-1 
RR-4 
RR-24 
13.4 ± 1.6 
14.2 ± 1.0 
14.7 ± 0.5 
138.3 ± 15.3
130.9 ± 19.7
128.0 ± 17.4
 87.6 ± 18.7
 89.7 ± 20.9
 80.0 ± 19.6
18.9 ± 4.2
18.7 ± 5.1
17.7 ± 3.9
13.8 ± 0.7
14.5 ± 0.6
14.9 ± 0.4
138.9 ± 15.0
127.4 ± 20.1
125.6 ± 13.5
 83.9 ± 15.3
 82.0 ± 16.5
 77.6 ± 15.8
19.2 ± 2.9
18.4 ± 2.3
18.3 ± 2.1
Values are expressed as mean ± SD. Group P: postoperative use 
of IV-PCA for pain control. Group N: intermittent analgesic drug 
administration for postoperative pain control. GCS: Glasgow Coma 
Scale, SBP (mmHg): systolic blood pressure, HR (beats/min): heart 
rate, RR (breaths/min): respiratory rate. 1, 4 and 24: at postoperative 
1, 4 and 24 hr respectively.  There were no significant differences 
between the two groups. 33 www.ekja.org
Korean J Anesthesiol Na, et al.
masking the signs of intracranial problems was not observed 
in both groups. There was no difference in the incidence of 
postoperative nausea between the two groups (35.8% vs. 32.1% 
for group P vs. group N, P = 0.501).
Discussion
    In this prospective, randomized controlled study, we proved 
that IV-PCA with fentanyl and ketorolac could provide superior 
analgesia in craniotomy patients without any major adverse 
events or any disturbances on the neurological examination. 
    IV-PCA is widely used to manage postoperative pain. It 
generally leads to greater patient satisfaction and better 
analgesic efficacy allowing the patients to exert self-control 
over their pain [16,17]. Nevertheless, in a survey of Stoneham 
and Walters [13], some neuroanesthesiologists indicated that 
the neurosurgical patients were too uncooperative to benefit 
from PCA. In addition, post-craniotomy pain has generally 
been treated inadequately [18,19] with a previous concept 
that post-craniotomy pain was not so severe and on-demand 
analgesic medication was enough [20,21]. Recently, however, 
postoperative pain control using the PCA does not thought to 
be the matter in neurosurgical department with a tendency 
towards waking up the patients in early postoperative period. 
Our patients also nearly regained consciousness at immediate 
postoperative time regardless of the group.
    To best of our knowledge, no previous study has investigated 
the use of IV-PCA combined with opioids and NSAIDs following 
craniotomy, although other types of PCA with morphine, 
oxycodone or fentanyl alone have been reported as suitable 
methods for pain control for this patient population [3,4,22]. We 
added the ketorolac to the intravenous fentanyl based PCA so 
we could achieve more distinct pain control in group P. 
    NSAIDs have a potential, although small, for causing postope-
rative bleeding by disturbing platelet function. This has caused 
the neuroanesthesiologists and neurosurgeons to have a passive 
attitude for using NSAIDs. However, none of our patients 
required an operation because of postoperative intracranial 
hematoma, although the number of our subjects was too 
small to draw firm conclusion about the safety of NSAIDs 
after craniotomy. Through this study, we can recommend that 
the proper use of NSAIDs may enhance analgesia without 
increasing the NSAID-related side effects, and the optimal 
supplementary dose of NSAIDs should be determined by future 
studies.
    As fentanyl is a roughly 50 to 100 times more potent lipophilic 
opioid than hydrophilic morphine [23], we choose it because 
of its more rapid onset than morphine and shorter duration 
when it is administered intravenously. We expected that these 
properties would reduce the postoperative pain during the 
early postoperative period. Also, with being used in continuous 
smaller doses, we thought fentanyl might cause analgesia 
during the recovery period without the accumulation or pro-
longed duration. Corresponding with this assumption, posto-
perative pain scores of group P were consistently lower than 
those of patients in group N.
    The infused volume via IV-PCA was very low (1 ml or a little 
more) at postoperative 1 hr, so the analgesic dose of group N 
could be more than that of group P. However, the difference 
of the amount of infused drug did not cause the difference of 
VASp at postoperative 1 hr. Interestingly, the smaller amount 
of infused drug of group P at postoperative 1 hr was reversed 
after postoperative 24 hr. The patients of group P received the 
analgesic drugs continuously throughout the period by the IV-
PCA, which contained the basal flow rate (1 ml/hr) with a bolus 
dose (1 ml). It would only be natural that the VASp became 
lower when more analgesic drug was administered via IV-PCA 
in group P. However, this study is valuable as it showed that IV-
PCA efficiently relieves postcraniotomy pain without interfering 
with the neurologic evaluation or lowering the GCS score, 
and this attests the ineffectiveness of intermittent analgesic 
injection, that is, insufficient analgesics and inadequate pain 
control shown in our group N. 
    Regardless of these affirmative results, what will be challen-
ging for using opioids clinically after craniotomy is probably 
the adverse events such as sedation, respiratory depression, 
nausea and vomiting. These opioid related side effects were rare 
in this present study, except for nausea. It was thought that the 
addition of ketorolac to intravenous fentanyl PCA might provide 
an opioid sparing and so reduce these events.
    We assessed the GCS scores of patients to evaluate the posto-
perative consciousness. Traditionally, coma using the GCS 
score is classified as severe with GCS ≤ 8, moderate with GCS 
9-12, and minor with GCS ≥ 13 [24]. Although a slightly lower 
GCS was assessed at postoperative 1 hr, it became over 14 from 
postoperative 4 hr in both groups. It means that the state of 
consciousness of group P was not different from that of group N. 
The patients had almost a minor coma status postoperatively, 
and actually there was no difficulty or erroneous masking when 
performing the neurologic examinations after the operation. 
Considering the report that fentanyl preserved cognitive 
function better than morphine [25], fentanyl is thought to be 
more appropriate to manage the moderate to severe pain of 
neurosurgical patients. 
    Our results also confirmed that the respiratory rate of both 
groups were not different. Prolonged ventilator care was 
not done except for the five cases of performing intentional 
sedation postoperatively. If we had measured the PaCO2 at each 
time point, it would have been sure to confirm specifically and 
objectively that fentanyl of IV-PCA had little effect on respiratory 34 www.ekja.org
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function. In addition, there was no difference in the incidence 
of nausea between the two groups. Although the IV-PCA was 
stopped in two patients of group P during the postoperative 
period due to vomiting, the overall incidence of nausea was 
similar in the two groups and antiemetic drugs improved that 
symptom. It has already been reported that intravenous opioid 
PCA-related nausea and vomiting were effectively reduced by 
antiemetic drugs [26]. Further study is needed concerning if IV-
PCA with pretreatment of antiemetic drugs can reduce the PCA-
related nausea and vomiting, and so it will be more effective in 
neurosurgical patients.
    We recognize several limitations of this study. First, when 
interpreting the GCS scores, it is notable that the individual 
elements as well as the sum of the GCS are important clinically. 
Anything among the eye, verbal and motor responses can 
influence the GCS score, however we just compared the total 
score and cannot distinguish which one was a major factor for 
lowering the score. Next, we did not create subgroups according 
to the surgical approach (supratentorial or infratentorial) or 
gender. There was a tendency of more intensive pain in females 
and infratentorial surgery as compared to the males and 
supratentorial surgery [19]. In contrast to the previous study, 
there were no significant differences with respect to gender 
or surgical approach in the present study. We assume that 
this could reach statistical significance with a large number 
of patients. Last, the number of enrolled patients was small to 
detect the incidence of adverse events. This study was designed 
to address the differences in pain control, not complications. 
Further larger patient population are needed to assess the safety 
issue. 
    In conclusion, our results suggest that IV-PCA with fentanyl 
and ketorolac provides better postoperative analgesia after 
craniotomy and this can be a safe and effective analgesic 
technique for neurosurgical patients. 
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